Challenges of endovascular tube graft repair of thoracic aortic aneurysm: Midterm follow-up and lessons learned

Sharif H. Ellozy, Alfio Carroccio, Michael Minor, Tikva Jacobs, Kristina Chae, Andrew Cha, Gautam Agarwal, Bethany Goldstein, Nicholas Morrissey, David Spielvogel, Robert A. Lookstein, Victoria Teodorescu, Larry H. Hollier, Michael L. Marin

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Objectives: Endovascular stent-graft repair has great potential in treatment of thoracic aortic aneurysms. This study analyzed a single center's experience with first-generation commercially produced thoracic stent grafts used to treat descending thoracic aortic aneurysms. Methods: Over 58 months 84 patients underwent endovascular stent-graft repair of descending thoracic aortic aneurysms; 22 patients received the Gore TAG stent graft, and 62 patients received the Talent thoracic endovascular stent-graft system. Each patient was enrolled in one of three distinct US Food and Drug Administration trials at Mount Sinai Medical Center in accordance with strict inclusion and exclusion criteria, including suitability for open surgery, aneurysm anatomy, and presence of comorbid medical illness. Mean age of this cohort was 71 ± 12 years. There were 54 men and 30 women, and 74 (88%) had three or more comorbid illnesses. Primary technical success was achieved in 76 patients (90%). Mean follow-up was 15 months (range, 0-52 months). Results: Successful aneurysm exclusion was achieved in 69 patients (82%). Major procedure-related or device-related complications occurred in 32 patients (38%). There were six proximal attachment failures (8%), four distal attachment failures (6%), one intergraft failure (1%), two mechanical device failures (3%), five periprocedural deaths (6%), and five late aneurysm ruptures (6%). At 40 months, overall survival was 67% (± 10%), and freedom from rupture or from type I or type III endoleak was 74% (±10%). Conclusion: While promising, this midterm experience with commercially available devices highlights the shortcomings of current stent-graft technology. Three significant advancements are required to fulfill the potential of this important treatment method: a stent graft with a durable proximal and distal fixation device, enhanced engineering to accommodate high thoracic aortic fatigue forces, and a mechanism to adapt to aortic arch and visceral segment branches to enable treatment of lesions that extend to or include these vessels.

Original languageEnglish (US)
Pages (from-to)676-683
Number of pages8
JournalJournal of Vascular Surgery
Volume38
Issue number4
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Thoracic Aortic Aneurysm
Stents
Transplants
Aneurysm
Thorax
Equipment and Supplies
Rupture
Equipment Failure
Endoleak
Aptitude
United States Food and Drug Administration
Thoracic Aorta
Fatigue
Anatomy
Therapeutics
Technology
Survival

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Challenges of endovascular tube graft repair of thoracic aortic aneurysm : Midterm follow-up and lessons learned. / Ellozy, Sharif H.; Carroccio, Alfio; Minor, Michael; Jacobs, Tikva; Chae, Kristina; Cha, Andrew; Agarwal, Gautam; Goldstein, Bethany; Morrissey, Nicholas; Spielvogel, David; Lookstein, Robert A.; Teodorescu, Victoria; Hollier, Larry H.; Marin, Michael L.

In: Journal of Vascular Surgery, Vol. 38, No. 4, 01.01.2003, p. 676-683.

Research output: Contribution to journalArticle

Ellozy, SH, Carroccio, A, Minor, M, Jacobs, T, Chae, K, Cha, A, Agarwal, G, Goldstein, B, Morrissey, N, Spielvogel, D, Lookstein, RA, Teodorescu, V, Hollier, LH & Marin, ML 2003, 'Challenges of endovascular tube graft repair of thoracic aortic aneurysm: Midterm follow-up and lessons learned', Journal of Vascular Surgery, vol. 38, no. 4, pp. 676-683. https://doi.org/10.1016/S0741-5214(03)00934-0
Ellozy, Sharif H. ; Carroccio, Alfio ; Minor, Michael ; Jacobs, Tikva ; Chae, Kristina ; Cha, Andrew ; Agarwal, Gautam ; Goldstein, Bethany ; Morrissey, Nicholas ; Spielvogel, David ; Lookstein, Robert A. ; Teodorescu, Victoria ; Hollier, Larry H. ; Marin, Michael L. / Challenges of endovascular tube graft repair of thoracic aortic aneurysm : Midterm follow-up and lessons learned. In: Journal of Vascular Surgery. 2003 ; Vol. 38, No. 4. pp. 676-683.
@article{4d20189431e74cffaceb92c234717f32,
title = "Challenges of endovascular tube graft repair of thoracic aortic aneurysm: Midterm follow-up and lessons learned",
abstract = "Objectives: Endovascular stent-graft repair has great potential in treatment of thoracic aortic aneurysms. This study analyzed a single center's experience with first-generation commercially produced thoracic stent grafts used to treat descending thoracic aortic aneurysms. Methods: Over 58 months 84 patients underwent endovascular stent-graft repair of descending thoracic aortic aneurysms; 22 patients received the Gore TAG stent graft, and 62 patients received the Talent thoracic endovascular stent-graft system. Each patient was enrolled in one of three distinct US Food and Drug Administration trials at Mount Sinai Medical Center in accordance with strict inclusion and exclusion criteria, including suitability for open surgery, aneurysm anatomy, and presence of comorbid medical illness. Mean age of this cohort was 71 ± 12 years. There were 54 men and 30 women, and 74 (88{\%}) had three or more comorbid illnesses. Primary technical success was achieved in 76 patients (90{\%}). Mean follow-up was 15 months (range, 0-52 months). Results: Successful aneurysm exclusion was achieved in 69 patients (82{\%}). Major procedure-related or device-related complications occurred in 32 patients (38{\%}). There were six proximal attachment failures (8{\%}), four distal attachment failures (6{\%}), one intergraft failure (1{\%}), two mechanical device failures (3{\%}), five periprocedural deaths (6{\%}), and five late aneurysm ruptures (6{\%}). At 40 months, overall survival was 67{\%} (± 10{\%}), and freedom from rupture or from type I or type III endoleak was 74{\%} (±10{\%}). Conclusion: While promising, this midterm experience with commercially available devices highlights the shortcomings of current stent-graft technology. Three significant advancements are required to fulfill the potential of this important treatment method: a stent graft with a durable proximal and distal fixation device, enhanced engineering to accommodate high thoracic aortic fatigue forces, and a mechanism to adapt to aortic arch and visceral segment branches to enable treatment of lesions that extend to or include these vessels.",
author = "Ellozy, {Sharif H.} and Alfio Carroccio and Michael Minor and Tikva Jacobs and Kristina Chae and Andrew Cha and Gautam Agarwal and Bethany Goldstein and Nicholas Morrissey and David Spielvogel and Lookstein, {Robert A.} and Victoria Teodorescu and Hollier, {Larry H.} and Marin, {Michael L.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0741-5214(03)00934-0",
language = "English (US)",
volume = "38",
pages = "676--683",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Challenges of endovascular tube graft repair of thoracic aortic aneurysm

T2 - Midterm follow-up and lessons learned

AU - Ellozy, Sharif H.

AU - Carroccio, Alfio

AU - Minor, Michael

AU - Jacobs, Tikva

AU - Chae, Kristina

AU - Cha, Andrew

AU - Agarwal, Gautam

AU - Goldstein, Bethany

AU - Morrissey, Nicholas

AU - Spielvogel, David

AU - Lookstein, Robert A.

AU - Teodorescu, Victoria

AU - Hollier, Larry H.

AU - Marin, Michael L.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objectives: Endovascular stent-graft repair has great potential in treatment of thoracic aortic aneurysms. This study analyzed a single center's experience with first-generation commercially produced thoracic stent grafts used to treat descending thoracic aortic aneurysms. Methods: Over 58 months 84 patients underwent endovascular stent-graft repair of descending thoracic aortic aneurysms; 22 patients received the Gore TAG stent graft, and 62 patients received the Talent thoracic endovascular stent-graft system. Each patient was enrolled in one of three distinct US Food and Drug Administration trials at Mount Sinai Medical Center in accordance with strict inclusion and exclusion criteria, including suitability for open surgery, aneurysm anatomy, and presence of comorbid medical illness. Mean age of this cohort was 71 ± 12 years. There were 54 men and 30 women, and 74 (88%) had three or more comorbid illnesses. Primary technical success was achieved in 76 patients (90%). Mean follow-up was 15 months (range, 0-52 months). Results: Successful aneurysm exclusion was achieved in 69 patients (82%). Major procedure-related or device-related complications occurred in 32 patients (38%). There were six proximal attachment failures (8%), four distal attachment failures (6%), one intergraft failure (1%), two mechanical device failures (3%), five periprocedural deaths (6%), and five late aneurysm ruptures (6%). At 40 months, overall survival was 67% (± 10%), and freedom from rupture or from type I or type III endoleak was 74% (±10%). Conclusion: While promising, this midterm experience with commercially available devices highlights the shortcomings of current stent-graft technology. Three significant advancements are required to fulfill the potential of this important treatment method: a stent graft with a durable proximal and distal fixation device, enhanced engineering to accommodate high thoracic aortic fatigue forces, and a mechanism to adapt to aortic arch and visceral segment branches to enable treatment of lesions that extend to or include these vessels.

AB - Objectives: Endovascular stent-graft repair has great potential in treatment of thoracic aortic aneurysms. This study analyzed a single center's experience with first-generation commercially produced thoracic stent grafts used to treat descending thoracic aortic aneurysms. Methods: Over 58 months 84 patients underwent endovascular stent-graft repair of descending thoracic aortic aneurysms; 22 patients received the Gore TAG stent graft, and 62 patients received the Talent thoracic endovascular stent-graft system. Each patient was enrolled in one of three distinct US Food and Drug Administration trials at Mount Sinai Medical Center in accordance with strict inclusion and exclusion criteria, including suitability for open surgery, aneurysm anatomy, and presence of comorbid medical illness. Mean age of this cohort was 71 ± 12 years. There were 54 men and 30 women, and 74 (88%) had three or more comorbid illnesses. Primary technical success was achieved in 76 patients (90%). Mean follow-up was 15 months (range, 0-52 months). Results: Successful aneurysm exclusion was achieved in 69 patients (82%). Major procedure-related or device-related complications occurred in 32 patients (38%). There were six proximal attachment failures (8%), four distal attachment failures (6%), one intergraft failure (1%), two mechanical device failures (3%), five periprocedural deaths (6%), and five late aneurysm ruptures (6%). At 40 months, overall survival was 67% (± 10%), and freedom from rupture or from type I or type III endoleak was 74% (±10%). Conclusion: While promising, this midterm experience with commercially available devices highlights the shortcomings of current stent-graft technology. Three significant advancements are required to fulfill the potential of this important treatment method: a stent graft with a durable proximal and distal fixation device, enhanced engineering to accommodate high thoracic aortic fatigue forces, and a mechanism to adapt to aortic arch and visceral segment branches to enable treatment of lesions that extend to or include these vessels.

UR - http://www.scopus.com/inward/record.url?scp=10744231885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231885&partnerID=8YFLogxK

U2 - 10.1016/S0741-5214(03)00934-0

DO - 10.1016/S0741-5214(03)00934-0

M3 - Article

C2 - 14560212

AN - SCOPUS:10744231885

VL - 38

SP - 676

EP - 683

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 4

ER -